NEW YORK, NY / ACCESS Newswire / February 24, 2025 / If you suffered a loss on your TransMedics Group, Inc. (NASDAQ:TMDX) investment and want to ...

In its upcoming report, TransMedics (TMDX) is predicted by Wall Street analysts to post quarterly earnings of $0.18 per share, reflecting an increase of 50% compared to the same period last year.

If you purchased or acquired securities in TransMedics between February 23, 2023 and January 10, 2025 and would like to ...

TransMedics is revolutionizing organ transplant therapy with its FDA-approved Organ Care System. See why I rate TMDX stock as ...

Van ECK Associates Corp grew its holdings in TransMedics Group, Inc. (NASDAQ:TMDX – Free Report) by 102.3% in the fourth ...

NEW YORK, Feb. 22, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against TransMedics Group, Inc. (NASDAQ: TMDX ...

The complaint alleges that TransMedics made false and misleading statements, while failing to disclose crucial information. Specifically, the suit contends that TransMedics used kickbacks ...

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today ...

LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...

Tuesday saw Canaccord Genuity reaffirm its Buy rating and $104.00 price target for TransMedics Group (NASDAQ:TMDX) shares, following the release of recent transplant data. The data, provided by the ...

TransMedics Group, Inc. (NASDAQ:TMDX – Get Free Report) has been given an average recommendation of “Moderate Buy” by the ...